BioCentury | Jul 29, 2020

Enthera’s €28M series A latest sign of growth for Italy’s biotech ecosystem

U.S. and European investors are backing the largest-ever series A financing for an Italian biotech, autoimmune play Enthera s.r.l. Enthera raised €28 million ($32.8 million) in the round, which was led by existing investor Sofinnova...
BioCentury | Aug 29, 2019
Distillery Techniques

STAT3-based gene signature to predict response to glioblastoma targeted therapy

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling A STAT3-based gene expression signature could identify glioblastoma multiforme (GBM) patients that will respond to STAT3 inhibitors as monotherapies or in combination with IGF1R (insulin-like growth factor-1 receptor; CD221)...
BioCentury | Jul 31, 2019
Financial News

Alizé seeks to build out company with largest European A round this year

French biotech Alizé Pharma 3 is taking a more ambitious approach than its predecessors, and now has a €67 million ($74.5 million) series A round to fund two endocrine programs through Phase II testing and...
BioCentury | Aug 9, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A biomanufacturing method could enable ex vivo production of human platelets to treat thrombocytopenia and other hematologic indications. In human induced pluripotent stem (iPS) cell-derived megakaryocyte cell lines cultured in shaking flasks,...
BioCentury | Jul 10, 2018
Distillery Therapeutics


INDICATION: Small cell lung cancer Patient sample and cell culture studies suggest promoting IGFBP5 expression or inhibiting POU2F3 or IGF1R could help treat POU2F3-expressing small cell lung cancer (SCLC). In tumor samples from SCLC patients,...
BioCentury | Jun 27, 2018
Preclinical News

New small cell lung cancer subtype identified

In a Genes & Development paper , scientists at Cold Spring Harbor Laboratory identified a new subtype of small cell lung cancer defined by high levels of POU class 2 homeobox 3 (POU2F3; OCT11) and suggest...
BioCentury | May 11, 2018

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May...
BioCentury | Feb 6, 2018
Distillery Therapeutics


INDICATION: Brain cancer Patient sample and mouse studies suggest promoting IGFBP3 expression could help treat MYCN-driven neuroblastoma. In five MYCN-driven neuroblastoma cell lines, IGFBP3 encoded by a plasmid vector decreased viability compared with GFP. In...
BioCentury | Aug 18, 2017
Emerging Company Profile

Teasing out Th1

EpiThany Inc. aims to increase the potency of therapeutic cancer vaccines by designing antigens that selectively activate immune-stimulating Th1 cells, without incurring the immunosuppressive effects caused by Th2 cell activation. Like most cancer vaccines in...
BioCentury | May 25, 2017

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
Items per page:
1 - 10 of 165